阅读说明：本技术 二氨基甲酰胺化合物的固体形式、其组合物及其使用方法 (Solid forms of diaminocarboxamide compounds, compositions thereof, and methods of use thereof ) 是由 安东尼奥·克里斯蒂安·费雷蒂 汉华·曼 亚莱·穆斯尔希丁诺格卢 珍·徐 凯文·辛-英·咏 于 2015-01-29 设计创作，主要内容包括：本文涉及2-(叔丁基氨基)-4-((1R,3R,4R)-3-羟基-4-甲基环己基氨基)-嘧啶-5-甲酰胺的固体形式、其组合物及其使用方法。本文提供了涉及2-(叔丁基氨基)-4-((1R,3R,4R)-3-羟基-4-甲基环己基氨基)-嘧啶-5-甲酰胺(化合物I)的制剂、工艺、固体形式和使用方法。另一方面,本文提供了用于制备某些化合物的方法,包括本文所述的化合物I,以及用于这样的方法的中间体。在某些方面中,化合物I的固体形式用于抑制表达所述激酶的细胞中的激酶,例如JNK1或JNK2。另一方面,化合物I的固体形式用于治疗或预防一种或多种障碍,所述障碍选自间质性肺纤维化、系统性硬化、硬皮病、慢性同种移植肾病、抗体介导的排斥反应或狼疮。(This document relates to solid forms of 2- (tert-butylamino) -4- ((1R, 3R, 4R) -3-hydroxy-4-methylcyclohexylamino) -pyrimidine-5-carboxamide, compositions thereof, and methods of use thereof. Provided herein are formulations, processes, solid forms and methods of use involving 2- (tert-butylamino) -4- ((1R, 3R, 4R) -3-hydroxy-4-methylcyclohexylamino) -pyrimidine-5-carboxamide (compound I). In another aspect, provided herein are processes for preparing certain compounds, including compound I described herein, as well as intermediates useful in such processes. In certain aspects, the solid form of compound I is used to inhibit a kinase, e.g., JNK1 or JNK2, in a cell expressing said kinase. In another aspect, the solid form of compound I is for use in the treatment or prevention of one or more disorders selected from the group consisting of interstitial pulmonary fibrosis, systemic sclerosis, scleroderma, chronic allograft nephropathy, antibody-mediated rejection or lupus.)